A Preface on Judgment

This is the kind of topic HonestLifter exists for -- one that the fitness industry handles badly. Let us establish something before we start: this article is not going to moralize about GLP-1 receptor agonists. We are not going to tell you that using semaglutide is "cheating." We are not going to imply that people who use it are lazy or lack discipline. That conversation is tired, unhelpful, and usually driven by people who have never been clinically obese.

We are also not going to pretend it is a magic solution with no trade-offs. It is a pharmaceutical intervention with significant effects on body composition, appetite regulation, and potentially muscle mass. Those effects deserve honest discussion, particularly for people who train.

Our job here is to give you the information. What you do with it is your business.

What Semaglutide Actually Is

Semaglutide is a GLP-1 receptor agonist -- GLP-1 stands for glucagon-like peptide-1. It was originally developed and approved for the treatment of type 2 diabetes (brand name Ozempic) and was subsequently approved at a higher dose for chronic weight management (brand name Wegovy). It is administered via a once-weekly subcutaneous injection.

Other GLP-1 receptor agonists on the market include liraglutide (Saxenda/Victoza) and tirzepatide (Mounjaro/Zepbound), which is technically a dual GIP/GLP-1 agonist. Tirzepatide has shown even more dramatic weight loss results in clinical trials and has become increasingly popular since its weight management approval.

The key thing to understand is that these are prescription medications developed for specific medical conditions. The off-label use for general weight loss in people who are not obese or do not have type 2 diabetes is widespread but falls outside the medications' approved indications.

How It Works: The Pharmacology

GLP-1 is an incretin hormone naturally produced in the gut in response to eating. It does several things:

Semaglutide mimics GLP-1 but is structurally modified to have a much longer half-life than the natural hormone (approximately 7 days vs. minutes). This means the appetite-suppressing and metabolic effects are sustained around the clock.

The weight loss results from clinical trials have been striking. The STEP trials showed average weight loss of approximately 15-17% of body weight over 68 weeks with semaglutide 2.4mg (Wegovy), compared to about 2-3% with placebo. Tirzepatide trials have shown even higher averages, in the range of 20-25% body weight loss at the highest doses.

These are not small numbers. For a 250-pound person, 15% body weight loss is 37.5 pounds. That is a life-changing amount of weight for someone struggling with obesity.

The Muscle Loss Problem

Here is where the fitness community's concerns are legitimate and worth taking seriously.

When you lose weight -- through any method -- you lose a combination of fat mass and lean mass (which includes muscle, water, glycogen, and organ tissue). The ratio of fat to lean mass loss depends on several factors: the rate of weight loss, protein intake, resistance training, initial body composition, and hormonal environment.

The general guideline from body composition research is that during a well-managed diet with adequate protein and resistance training, about 75-80% of weight lost should come from fat and 20-25% from lean mass. In poorly managed rapid weight loss without exercise or adequate protein, the lean mass loss can be much higher -- sometimes approaching 40-50% of total weight lost.

What the GLP-1 Data Shows

The STEP 1 trial reported that approximately 39% of weight lost with semaglutide was lean body mass. This is higher than the 25% typically seen with diet-and-exercise interventions. However, there are important caveats to this number:

A critical point: we do not have good data on what happens to lean mass when GLP-1 use is combined with structured resistance training and high protein intake. The trials that produced the concerning lean mass numbers did not control for these variables. It is plausible -- and some preliminary research suggests -- that the lean mass loss can be significantly mitigated with proper training and nutrition.

Important Caveat

This article is informational and is not medical advice. GLP-1 receptor agonists are prescription medications with potential side effects and contraindications. Any decision about using these medications should be made with a qualified healthcare provider who understands your individual medical history.

Training on a GLP-1: What to Adjust

If you are using or considering a GLP-1 agonist and you train regularly, here are the evidence-informed training adjustments that make sense:

Prioritize Resistance Training Over Cardio

The medication is already creating a significant caloric deficit through appetite suppression. You do not need to pile excessive cardio on top of it. The primary role of exercise in this context should be to preserve muscle mass, and resistance training is far superior to cardio for that purpose.

This does not mean eliminate cardio entirely. Cardiovascular health matters, and 2-3 sessions of moderate-intensity cardio per week (walking, cycling, swimming) is reasonable. But your training priority should be getting into the weight room 3-4 times per week.

Maintain Training Intensity

One of the biggest mistakes people make during any weight loss phase is dramatically reducing training loads. When calories are restricted (whether voluntarily or through medication-induced appetite suppression), there is a natural tendency to reduce intensity because you feel less energetic.

Resist this. The stimulus that tells your body to preserve muscle is lifting heavy (relative to your capacity) weights. You may need to reduce total volume (fewer sets) to manage recovery in a deficit, but the intensity (load per set, proximity to failure) should remain high.

A practical approach: maintain your working weights as long as possible, but reduce total sets per muscle group by 20-30% compared to your maintenance or surplus training. If you were doing 16 sets per muscle group per week, drop to 10-12. Keep the weight on the bar.

Focus on Compound Movements

In a significant caloric deficit, your recovery capacity is limited. Compound movements (squats, deadlifts, bench press, rows, overhead press) give you the most muscle-preserving stimulus per unit of fatigue. This is not the time for 5 different bicep curl variations. Get in, hit the big lifts hard, add a few key isolation exercises for lagging areas, and get out.

Monitor Performance and Adjust

Track your lifts. If your strength is declining steadily week over week beyond the first few weeks of adjustment, something needs to change. Possible interventions include: reducing volume further, adjusting caloric intake (potentially eating more), slowing the rate of weight loss by adjusting medication dose (with your doctor), or adding a diet break.

Be Realistic About Energy Levels

GLP-1 agonists suppress appetite significantly. Some users report nausea, particularly in the early weeks. Your training sessions may not feel the same as they do when you are eating at maintenance or in a surplus. Accept this. A productive but slightly lower-energy training session is infinitely better than skipping the gym because you do not feel 100%.

Sample Weekly Training Structure on a GLP-1

For someone on a GLP-1 agonist who was previously training 5-6 days per week, a reasonable adjusted schedule might look like this:

Notice the reduced volume compared to a typical hypertrophy program. When you are in a significant caloric deficit (which GLP-1 users invariably are), recovery capacity is diminished. The goal shifts from maximizing muscle growth to preserving existing muscle. That requires intensity (heavy relative loads) but not the same volume you would use in a surplus.

The key principles: keep compound movements as the foundation, maintain the heaviest loads you can handle with good form, reduce total set count by 25-30% from your surplus training, and do not add excessive cardio on top. The medication is already creating the caloric deficit. Your job in the gym is to give your muscles a reason to stick around.

Nutrition Considerations

Protein Is Non-Negotiable

If there is one single variable that determines how much muscle you preserve during weight loss -- whether on a GLP-1 or not -- it is protein intake. The research consistently shows that higher protein intakes during caloric restriction lead to greater preservation of lean body mass.

The general recommendation for protein during a deficit, based on multiple systematic reviews, is 1.6 to 2.2 grams per kilogram of body weight per day (approximately 0.7 to 1.0 grams per pound). If you are significantly overweight, use your target body weight or lean body mass as the basis for the calculation rather than total body weight.

The challenge with GLP-1 agonists is that appetite suppression can make it genuinely difficult to consume enough protein. Many users report that eating feels like a chore. This is where protein supplementation (whey protein shakes, casein, or other sources) becomes practically important. Liquid calories are easier to consume when appetite is low.

Do Not Eat Too Little

Some GLP-1 users, particularly those excited by rapid weight loss, allow their caloric intake to drop to dangerously low levels -- sometimes under 800 calories per day. This is counterproductive for multiple reasons:

A reasonable caloric deficit for someone on a GLP-1 who is training is in the range of 500-750 calories below maintenance. If the medication suppresses your appetite below this level, you need to make a conscious effort to eat more. This is one of those situations where tracking caloric intake, even roughly, becomes important.

Prioritize Food Quality

When your total food intake is reduced, every meal matters more from a nutrient density standpoint. Focus on protein-rich whole foods, vegetables, fruits, and whole grains. This is not the time for a "if it fits your macros" approach where you fill your reduced caloric budget with processed foods. You need vitamins, minerals, and fiber from quality food sources.

Stay Hydrated

GLP-1 agonists slow gastric emptying, which can contribute to nausea and reduced fluid intake. Dehydration impairs training performance, recovery, and general health. Make a conscious effort to drink adequate water throughout the day -- a reasonable target is roughly half your body weight in ounces.

Who Actually Benefits

Based on the clinical evidence and the approved indications, the people who stand to benefit most from GLP-1 receptor agonists are:

The use case that generates the most debate is people who are mildly overweight or at a normal weight using these medications for cosmetic reasons -- to lose the last 10-15 pounds or achieve a leaner physique. The clinical trial data for this population is limited, and the risk-benefit calculation is less clear.

We are not going to tell you what to do. But we will point out that if you are already at 15% body fat and training regularly, a GLP-1 agonist is a pharmaceutical intervention for a problem that can almost certainly be solved with dietary adjustments and patience. The medication has side effects and potential long-term unknowns. Whether those risks are worth it for cosmetic fat loss in an already healthy person is a personal decision that should be made with full awareness of the trade-offs.

The Fitness Community Debate

The fitness community's response to GLP-1 agonists has been, predictably, polarized.

On one side, you have people who view any pharmacological weight loss assistance as fundamentally "wrong" -- a shortcut that undermines the discipline and hard work that fitness is supposed to represent. This perspective often comes from people who have never experienced clinical obesity, food addiction, or the metabolic adaptations that make sustained weight loss extremely difficult for some populations.

On the other side, you have people who view GLP-1 agonists as the solution to the obesity epidemic -- a pharmaceutical breakthrough that removes the "willpower" component from weight management and treats obesity as the complex metabolic disease that it is. This perspective sometimes downplays the legitimate concerns about muscle loss, long-term side effects, and the challenge of weight regain when the medication is discontinued.

The HonestLifter take sits somewhere in between. These medications represent a genuinely significant development in the treatment of obesity and metabolic disease. They are helping millions of people lose weight who had failed with diet and exercise alone. That is real and meaningful.

But they are not without trade-offs. The muscle loss data is concerning, particularly for long-term metabolic health (muscle mass is the single largest contributor to resting metabolic rate and glucose disposal). The weight regain data when medication is stopped is also concerning -- most studies show significant weight regain within a year of discontinuation. And the long-term safety profile beyond 2-3 years is still being established.

The reasonable position is: these are powerful medical tools that should be used appropriately, ideally under medical supervision, and in combination with resistance training and adequate nutrition. They are not a substitute for building sustainable lifestyle habits, because you will likely need to maintain those habits whether you stay on the medication or eventually come off it.

The Weight Regain Problem

One of the least-discussed aspects of GLP-1 therapy is what happens when you stop taking it. This is not a minor detail -- it is arguably the most important consideration for anyone thinking about starting these medications.

The STEP 1 extension trial followed participants after they discontinued semaglutide. Within one year of stopping the medication, participants regained approximately two-thirds of the weight they had lost. Hunger levels returned to pre-medication baselines. The metabolic benefits (improved blood sugar, cholesterol, blood pressure) also reversed proportionally to the weight regained.

This should not be surprising from a pharmacological standpoint. GLP-1 receptor agonists work by modifying the signaling environment in your body. When you remove the drug, the signaling returns to its pre-treatment state. The medication is not curing anything -- it is managing a condition. In that sense, it is more analogous to blood pressure medication (which must be taken continuously to maintain its effect) than to an antibiotic (which resolves the underlying infection).

What This Means for Fitness-Minded Users

If you are using a GLP-1 agonist to reach a target weight, you need a realistic plan for what happens after. There are essentially three paths:

  1. Stay on the medication indefinitely. This is what many physicians now recommend for clinical obesity, treating it as a chronic condition requiring ongoing management. The long-term data beyond 3-4 years is still limited, and the cost implications are significant (these medications are expensive, and insurance coverage varies).
  2. Taper off and rely on established lifestyle habits. This requires building strong exercise and nutrition habits while on the medication, so that when you taper off, you have behavioral infrastructure in place to manage your weight. This is the ideal scenario but requires genuine commitment to lifestyle change while the medication makes things easier.
  3. Stop and accept some weight regain. Many people will regain some but not all of the weight. If you lost 60 pounds and regain 20, you are still 40 pounds lighter than when you started. That is still a meaningful health improvement, even if it is not the full result you achieved on medication.

The worst approach is to use the medication without building any sustainable habits, lose the weight, stop the medication, and then be surprised when the weight comes back. This is not the medication failing -- it is a failure of planning.

The Cost Factor

We would be irresponsible not to mention cost, because it is a major barrier for many people and a source of significant frustration.

The list price for semaglutide (Wegovy) has been roughly $1,300-1,400 per month without insurance. Tirzepatide (Zepbound) is in a similar range. Insurance coverage is inconsistent -- some plans cover it for obesity, others only for diabetes, and many exclude weight-management medications entirely.

The compounding pharmacy market emerged as a lower-cost alternative, with compounded semaglutide available for significantly less. However, this market has been subject to regulatory scrutiny, and the quality and reliability of compounded products varies. The FDA has expressed concerns about some compounded GLP-1 products not meeting pharmaceutical standards.

If you are considering these medications, factor in the total cost over time, not just the per-month cost. If the plan is to use the medication for 12-18 months, the total expenditure can easily reach $15,000-$25,000 out of pocket. Whether that cost is justified depends on your financial situation, your health risks from obesity, and how you weigh the alternatives.

The Bottom Line

Here is what we know with reasonable confidence:

  1. GLP-1 receptor agonists produce significant weight loss through appetite suppression and metabolic effects. The clinical data is strong.
  2. Lean mass loss is a real concern, particularly without resistance training and adequate protein. The clinical trial data shows higher-than-ideal lean mass loss, but those trials did not control for exercise or protein intake.
  3. Resistance training and high protein intake are the two most important interventions for preserving muscle during any weight loss, including medication-assisted weight loss. If you are on a GLP-1 and not lifting weights, you should start.
  4. The medications are not a standalone solution. Weight regain after discontinuation is common. Building sustainable eating and exercise habits while on the medication is essential for long-term success.
  5. The judgment and moralizing from the fitness community is unhelpful. Obesity is a complex, multifactorial condition. Effective tools for managing it should be welcomed, not stigmatized.
  6. If you are considering these medications, talk to a doctor. Not a fitness influencer. Not an online forum. A qualified healthcare provider who can evaluate your individual situation, risks, and goals.

We do not have a strong opinion on whether any specific individual should or should not use GLP-1 agonists. That is a medical decision between you and your doctor. What we at HonestLifter do have a strong opinion about is that anyone using these medications should be lifting weights and eating sufficient protein. The data is too clear on muscle loss risks to ignore those interventions.

And regardless of how you feel about these medications, their existence does not change the fundamentals. Training hard, eating well, sleeping enough, and being consistent -- those things matter whether you are on a GLP-1 or not. At HonestLifter, we will always come back to the basics because the basics never go out of style.

Frequently Asked Questions

Does semaglutide cause muscle loss?

Yes, muscle loss is a legitimate concern with semaglutide. The STEP 1 clinical trial found that approximately 39% of weight lost was lean body mass, which is higher than the 25% typically seen with standard diet-and-exercise weight loss. However, trial participants were not performing resistance training or consuming optimized protein intake. Lean body mass also includes water, glycogen, and organ tissue, not just skeletal muscle. Resistance training 3-4 times per week and protein intake of 1.6-2.2g per kilogram of body weight per day can significantly mitigate muscle loss.

Can you take semaglutide and build muscle?

Building new muscle while on semaglutide is very difficult because the medication creates a significant caloric deficit through appetite suppression. Building muscle generally requires a caloric surplus or at least maintenance calories. The realistic goal while on a GLP-1 agonist is muscle preservation, not muscle growth. To preserve as much muscle as possible, prioritize resistance training 3-4 days per week with heavy compound movements, consume at least 1.6g of protein per kilogram of body weight daily, and avoid extreme caloric deficits below 500-750 calories under maintenance.

How much does semaglutide cost without insurance?

The list price for semaglutide (Wegovy) is roughly $1,300-1,400 per month without insurance as of 2026. Tirzepatide (Zepbound) is in a similar price range. Insurance coverage varies widely -- some plans cover it for obesity, others only for diabetes, and many exclude weight-management medications entirely. Compounding pharmacies offer lower-cost alternatives, though quality varies and the FDA has raised concerns about some compounded products. Over a typical 12-18 month course of treatment, out-of-pocket costs can reach $15,000-25,000.

Do you gain weight back after stopping semaglutide?

The data strongly suggests yes. The STEP 1 extension trial found that participants regained approximately two-thirds of the weight they had lost within one year of stopping semaglutide. Hunger levels returned to pre-medication baselines, and metabolic benefits reversed proportionally to weight regained. The medication manages the condition rather than curing it, similar to blood pressure medication. Building sustainable exercise and nutrition habits while on the medication is critical for long-term success, whether you plan to stay on it indefinitely or eventually taper off.

Is semaglutide safe long term?

The long-term safety profile of semaglutide beyond 3-4 years is still being established. Common side effects include nausea (especially during dose escalation), vomiting, diarrhea, and constipation. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, which is a significant safety benefit for at-risk populations. There are ongoing investigations into potential associations with thyroid tumors (seen in rodent studies), pancreatitis, and gallbladder issues. Any decision about long-term use should be made with a qualified healthcare provider who can evaluate your individual risk profile.